Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Integrin αVβ5 is a heterodimeric cell surface receptor composed of integrin alpha V (ITGAV) and integrin beta 5 (ITGB5) subunits. It mediates cell adhesion to vitronectin via the RGD motif and participates in endocytosis, signal transduction, and angiogenesis. It is expressed on various cell types and is considered a potential therapeutic target in diseases involving abnormal angiogenesis or tumor progression.
RGD motif binding inhibitors
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Integrin alpha-V beta5 (αVβ5).